A 58-year-old woman from Bangalore with Parkinson's disease of 8 years' duration is on levodopa-carbidopa and has developed severe motor fluctuations and dyskinesias. She is now started on entacapone. Within 3 days of starting the drug, she develops diarrhea, dark urine, and mild elevation of liver enzymes (ALT 85 U/L, AST 92 U/L). She also reports increased dyskinesias. Which of the following is the most likely explanation for her symptoms?

Explanation

## Entacapone: Mechanism, Pharmacokinetics, and Adverse Effects ### Drug Class and Mechanism **Key Point:** Entacapone is a **catechol-O-methyltransferase (COMT) inhibitor** that blocks the peripheral metabolism of levodopa, increasing its bioavailability and prolonging its half-life. ### Pharmacokinetic Effect of COMT Inhibition COMT is responsible for methylating levodopa in the periphery (and to some extent in the CNS). By inhibiting COMT: 1. **Levodopa clearance decreases** → higher peak plasma levels 2. **Levodopa half-life increases** from ~60 minutes to ~90 minutes 3. **Brain dopamine levels increase** → more pronounced dopaminergic effects (both therapeutic and adverse) 4. **Entacapone requires dose reduction of levodopa** (typically 10–30% reduction) to prevent overdose ### Clinical Consequences in This Patient The patient was NOT given a reduced levodopa dose after starting entacapone. Therefore: - **Increased levodopa bioavailability** → higher dopamine levels in the brain - **Worsening dyskinesias** → predictable consequence of excess dopamine at peak levels - **Diarrhea** → increased dopamine in the GI tract (dopamine inhibits acetylcholine, but in the colon, excess dopamine can cause secretory diarrhea via peripheral D2 receptors) - **Dark urine** → entacapone is metabolized to a dark metabolite (3-O-methyldopa conjugate); this is a **benign, expected finding**, not hepatotoxicity - **Mild transaminitis** → can occur early with entacapone but is usually transient and not clinically significant; it does NOT require drug discontinuation unless severe (>3× ULN) or symptomatic ### Why This Is NOT Hepatotoxicity **Clinical Pearl:** The combination of dark urine + mild transaminitis in an entacapone-treated patient is a **classic benign pattern**. The dark urine is pathognomonic for entacapone use (due to its metabolite) and indicates the drug is working, not causing harm. ### Management | Finding | Interpretation | Action | |---------|-----------------|--------| | Dark urine | Entacapone metabolite excretion | Reassure patient; benign | | Mild ALT/AST elevation (1–2× ULN) | Transient, usually self-limited | Monitor; continue drug | | Worsening dyskinesias | Excess dopamine from ↑ levodopa bioavailability | **Reduce levodopa dose by 10–30%** | | Diarrhea | Peripheral dopamine effects | Dietary modification; rarely requires discontinuation | **High-Yield:** Entacapone does NOT cause significant hepatotoxicity at therapeutic doses. The dark urine is a **reassuring sign** that the drug is being metabolized and excreted normally. ### Correct Management 1. **Do NOT discontinue entacapone** based on mild transaminitis 2. **Reduce levodopa dose** to compensate for increased bioavailability 3. **Monitor LFTs** — if ALT/AST exceed 3× ULN or patient develops jaundice/RUQ pain, then consider discontinuation 4. **Reassure about dark urine** — it is expected and benign **Mnemonic: COMT-I (COMT Inhibitor) Side Effects = "DARK"** - **D**ark urine (metabolite) - **A**dverse effects from excess dopamine (dyskinesias, nausea) - **R**equires levodopa dose **R**eduction - **K**eep monitoring (LFTs, but usually benign) [cite:KD Tripathi 8e Ch 16; Harrison 21e Ch 427]